Ronnie Blount, MD
Psychiatry · Milledgeville, GANPI 1720159098
Payments from drug & device makers
What this record shows
This record is dominated by other: $84,418 of the $87,630 with a category attached, or 96.3%. Neuronetics, Inc. accounts for 96.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $84,870 and has fallen 98.9% since, to $945 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $458.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$84K
- Lundbeck LLC$518
- AbbVie$456
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$424
- Takeda Pharmaceuticals U.S.A., Inc.$345
- Otsuka America Pharmaceutical, Inc.$319
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,2124%
- Other$84,41896%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 1 | $84,418 |
| Lundbeck LLC | 28 | $518 |
| AbbVie(2 entities) | 32 | $456 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $424 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $345 |
| Otsuka America Pharmaceutical, Inc. | 17 | $319 |
| Teva Pharmaceuticals USA, Inc. | 12 | $210 |
| Idorsia Pharmaceuticals US Inc | 7 | $129 |
| Alkermes, Inc. | 7 | $129 |
| Neurocrine Biosciences, Inc. | 5 | $104 |
| Eisai Inc. | 6 | $88 |
| Johnson & Johnson | 4 | $81 |
| Harmony Biosciences LLC | 3 | $71 |
| Sunovion Pharmaceuticals Inc. | 3 | $57 |
| Bausch Health US, LLC | 2 | $40 |
| Indivior Inc. | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 2 | $29 |
| Tempus AI, Inc | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Merck | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Noven Therapeutics, LLC | 1 | $13 |
| Orexo US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$84,418
How this compares
$87,630 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 43 | $75,259 |
| VraylarCariprazine Hcl | 43 | $63,753 |
| TrintellixVortioxetine Hydrobromide | 104 | $49,650 |
| Invega SustennaPaliperidone Palmitate | 13 | $48,026 |
| Chlorpromazine Hcl | 112 | $23,569 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 99 | $17,956 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $12,793 |
| VyvanseLisdexamfetamine Dimesylate | 28 | $11,455 |
| Quetiapine Fumarate | 562 | $11,352 |
| InvegaPaliperidone | 12 | $7,120 |
| Alprazolam | 1,201 | $6,222 |
| Trazodone Hcl | 729 | $6,020 |
| Divalproex Sodium ErDivalproex Sodium | 154 | $5,913 |
| Haloperidol | 96 | $5,368 |
| Benztropine Mesylate | 427 | $5,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $319 | $75,25943 claims |
| AbbVieVraylar | $456 | $63,75343 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $345 | $61,104132 claims |
| Johnson & JohnsonInvega Sustenna, Invega | $81 | $55,14625 claims |
| Indivior Inc.Suboxone | $39 | $12,79317 claims |
| MerckBelsomra | $14 | $4,89812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Milledgeville
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
- Michael BurkeAtlanta$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.